The approval stipulates use in advanced, unresectable, or metastatic disease that progressed on prior systemic therapy.
On December 4, 2024, the Food and Drug Administration granted accelerated approval to Merus (MRUS)’ zenocutuzumab-zbco for adults with the ...
The systemic agent is the first approved by the FDA for patients with NSCLC or pancreatic adenocarcinoma harboring an NRG1 gene fusion.
Merus (MRUS) announced that the FDA approved BIZENGRI(R) (zenocutuzumab-zbco), the first and only treatment indicated for ...
The FDA has approved the first systemic therapy for patients with NSCLC or pancreatic adenocarcinoma with an NRG1 gene fusion.